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Abstract 
Objectives 
Processed electroencephalogram-based depth of anaesthesia monitoring devices provide an 
additional method to monitor level of consciousness during procedural sedation and 
analgesia. The objective of this systematic review was to determine whether using a depth 
of anaesthesia monitoring device improves the safety and efficacy of sedation. 
Design 
Systematic review and meta-analysis. 
Data sources 
Electronic databases (CENTRAL; Medline; CINAHL) were searched up to May 2015.  
Review methods 
Randomized controlled trials that compared use of a depth of anaesthesia monitoring 
device to a control group who received standard monitoring during procedural sedation and 
analgesia were included. Study selection, data extraction and risk of bias assessment 
(Cochrane risk of bias tool) were performed by two reviewers. Safety outcomes were 
hypoxaemia, hypotension and adverse events. Efficacy outcomes were amount of sedation 
used, duration of sedation recovery and rate of incomplete procedures.  
Results 
A total of 16 trials (2138 participants) were included. Evidence ratings were downgraded to 
either low or moderate quality due to study limitations and imprecision. Meta-analysis of 8 
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trials (766 participants) found no difference in hypoxaemia (RR 0.87; 95% CI=0.67 to 1.12). 
No statistically significant difference in hypotension was observed in meta-analysis of 8 trials 
(RR 0.96; 95% CI=0.54 to 1.7; 942 participants). Mean dose of propofol was 51mg lower for 
participants randomised to depth of anaesthesia monitoring (95% CI=-88.7 to -13.3mg) in 
meta-analysis of results from four trials conducted with 434 participants who underwent 
interventional endoscopy procedures with propofol infusions to maintain sedation. The 
difference in recovery time between depth of anaesthesia and standard monitoring groups 
was not clinically significant (standardised mean difference -0.41; 95% CI -0.8 to -0.02; 
I2=86%; 8 trials; 809 participants).  
Conclusions 
Depth of anaesthesia monitoring did impact sedation titration during interventional 
procedures with propofol infusions. For this reason, it seems reasonable for anaesthetists to 
utilise a depth of anaesthesia monitoring device for select populations of patients if it is 
decided that limiting the amount of sedation would be beneficial for the individual patient. 
However, there is no need to invest in purchasing extra equipment or training staff who are 
not familiar with this technology (e.g. nurses who don’t routinely use a depth of anaesthesia 
monitoring device during general anaesthesia) because there is no high quality evidence 
suggestive of clear clinical benefits for patient safety or sedation efficacy. 
Keywords: 
Procedural sedation and analgesia; Conscious sedation, Deep sedation, Bispectral index, 
Depth of Anaesthesia monitor  
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Background 
Frequent monitoring of level of consciousness is recommended during procedural sedation 
and analgesia so that corrective interventions can be implemented if patients enter a level 
of sedation that is deeper or lighter than intended (ANZCA, 2014, Gross et al., 2002). An 
example of a corrective intervention would be to reduce or increase the infusion rate of 
sedation medications. Level of consciousness is usually monitored using clinical observation 
by judging a sedated patient’s response to increasing levels of stimulation (Sheahan and 
Mathews, 2014). Standardised sedation assessment scales that assign numerical ranks to 
observable clinical behaviours known to be associated with changes in the level of 
consciousness are used to supplement clinical observation methods for assessing changes in 
level of consciousness during procedural sedation and analgesia.  Electroencephalogram-
based depth of anaesthesia monitoring devices can provide an additional method to 
monitor level of consciousness that can be used to supplement clinical observation.  
Although interpretation of raw electroencephalograms can be used to monitor depth of 
anaesthesia, processed electroencephalogram-based depth of anaesthesia monitoring 
devices, such as the Bispectral IndexTM (Covidien, Inc., Boulder, CO, USA), are more common 
in anaesthetic practice (Rampil, 1998). The Bispectral IndexTM device calculates a numerical 
derivative from brain electrical activity. It is calculated from an electroencephalogram 
measured at the forehead. Bispectral IndexTM values range between 0, which represents a 
state of ‘no detectable brain electrical activity’, and 100, which represents the ‘awake’ state 
(Johansen, 2006). Values below 60 correspond to ‘deep’ sedation (Glass et al., 1997). Other 
depth of anaesthesia monitors which use proprietary algorithms to process 
electroencephalogram information include the E-Entropy (GE Healthcare) and Narcotrend-
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Compact M monitors (MT Monitor Technik). Similar to the Bispectral IndexTM, both of these 
monitors produce numerical values to represent different states of the depth of 
anaesthesia. 
Evaluation of the potential clinical benefits of using depth of anaesthesia monitoring during 
procedural sedation and analgesia, including syntheses of the available evidence, is 
required. One important potential clinical benefit of using depth of anaesthesia monitoring 
during procedural sedation and analgesia is that this technology could improve patient 
safety. Potentially, earlier identification of lapses into deeper than intended levels of 
sedation using depth of anaesthesia monitors can lead to more effective titration of 
sedative and analgesic medications, resulting in a reduction in the risk of sedation-related 
adverse events caused by over-sedation, such as inadequate oxygenation/ventilation or 
circulation. Another potential clinical benefit is that depth of anaesthesia monitoring could 
improve detection of situations where depth of sedation is insufficient, which could lead to 
increased procedural-related pain and stress. The objective of this review was to determine 
whether using depth of anaesthesia monitoring during procedural sedation and analgesia in 
the hospital setting improves patient safety and sedation efficacy.  
Methods 
A systematic review and meta-analyses adhering to our published protocol was conducted 
(Conway and Sutherland, 2015).  
Eligibility criteria and literature search 
Studies meeting the following criteria were included: Design - Parallel and cross-over 
randomized controlled trials; Population - patients (adults or children) who received 
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procedural sedation and analgesia (with or without local anaesthesia) in any inpatient or 
outpatient setting where procedural sedation and analgesia was used in a hospital (studies 
that included patients who received general or regional anaesthesia were excluded from the 
review); Intervention - Depth of anaesthesia monitoring, such as Bispectral IndexTM, E-
Entropy and Narcotrend, was used in addition to clinical judgement and/or a specified 
clinical sedation assessment tool to monitor consciousness; Comparison – control group 
where depth of anaesthesia monitoring was not used to monitor consciousness (only clinical 
judgement and/or a specified clinical sedation assessment tool was used); Outcomes - 
Hypoxaemia (as defined by the study authors); Hypotension (as defined by the study 
authors), amount of sedative and analgesic medications used (a separate analysis was 
undertaken for each medication), duration of recovery from sedation (as defined by the 
study authors); number of procedures not completed as planned due to inadequate 
sedation; and sedation-related adverse events (e.g. death, neurological deficits, assisted 
ventilation).  
We identified published, unpublished and ongoing studies by searching the following 
databases: The Cochrane Central Register of Controlled Trials (CENTRAL) (1999 (established) 
to 1st May 2015); MEDLINE (OvidSP) (1966 to 1st May 2015); CINAHL (EBSCOhost) (1982 to 
1st May 2015); ClinicalTrials.gov; and World Health Organization International Clinical Trials 
Registry Platform. The search strategy (S1 Appendix) was designed by applying the guidance 
of the Cochrane Handbook for Systematic Reviews of Interventions, Chapter 6.4. Language 
restrictions were not imposed. Initial screening of titles and abstracts was performed by two 
independent reviewers (AC and JS). Full copies of all studies that met the inclusion criteria 
were obtained for further assessment. Second screening of full text articles was performed 
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by two independent reviewers (AC and JS) applying all inclusion and exclusion criteria 
outlined in the review protocol (S2 Table). Disagreement on eligibility was resolved by 
discussion. 
Data extraction and assessment of risk of bias  
Data was independently extracted by two reviewers using the data extraction form (S2 
Table). Any differences of opinion were reconciled by mutual agreement. Data was entered 
into a database (Review Manager (RevMan), Version 5) for statistical analysis. Risk of bias 
assessment of the included studies was conducted independently, as guided by the 
Cochrane Handbook for Systematic Reviews of Interventions. The Cochrane risk of bias tool 
was used to assign a judgment about the degree of risk (low risk of bias, high risk of bias and 
unclear risk of bias) (S2 Table).  
Statistical analysis 
Risk ratios for dichotomous data and mean difference for continuous data with 
corresponding 95% CIs were calculated. The unit of analysis was based on the individual 
patient (the unit that was randomized for comparison of interventions). We planned to use 
pre-crossover data for included trials that used a crossover design. Intention-to-treat 
analyses were performed. To assess statistical heterogeneity we applied the chi-squared 
test, as a low p value is evidence of the heterogeneity of intervention effects. In addition to 
statistical assessments we qualitatively reviewed studies by examining variability in study 
participants, interventions and outcomes. In the absence of clinical heterogeneity, we used 
the I2 statistic to describe the percentage of total variation across studies that is due to the 
heterogeneity rather than chance. An I2 value greater than 50% was considered significant 
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heterogeneity. We also visually inspected the graphical representation of study results with 
their 95% CIs to assess heterogeneity. We used the fixed-effect model meta-analysis except 
where statistical or clinical heterogeneity was identified. We performed meta-analyses using 
RevMan software (Version 5.3). We conducted subgroup analysis based on: age (adults or 
children); use of supplemental oxygen (used routinely or not); use of end-tidal carbon 
dioxide monitoring (used or not); the type of sedation regimen used (propofol, 
benzodiazepine, benzodiazepine and opioid combination, ketamine, dexmedetomidine, 
other); the type of depth of anaesthesia monitoring device used; and the type of procedure 
(diagnostic or interventional). Principles of the GRADE (Grades of Recommendation, 
Assessment, Development and Evaluation) system were used to assess the quality of the 
body of evidence associated with specific outcomes (hypoxaemia, hypotension, sedation 
doses and procedural completion) (Guyatt et al., 2008).  
Results 
Overall, 18 publications from 232 citations were identified as potentially relevant. The 
remainder were clearly irrelevant, most either utilised study designs other than a 
randomised controlled trial or examined a different intervention. A total of 16 trials (2138 
participants) were included. Exclusions are detailed in Figure 1.   
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Figure 1. PRISMA flow diagram 
 
A summary of the trial characteristics is presented in Table 1. Included trials were conducted 
in a range of clinical settings including paediatric cardiology (Baysal et al., 2008), 
interventional radiology (Dahaba et al., 2006), bronchoscopy (Fruchter et al., 2014, Lo et al., 
2011), endoscopy (DeWitt, 2008, Drake et al., 2006, Imagawa et al., 2008, Jang et al., 2012, 
Kang et al., 2011, Park et al., 2014, Paspatis et al., 2009, von Delius et al., 2012, Wehrmann 
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et al., 2002, Yu et al., 2013), orthopaedics (Lin et al., 2011) and emergency departments 
(Miner et al., 2003). One study used raw electoencephalograms for depth of anaesthesia 
monitoring and another used A-line autoregressive index of the auditory evoked potential 
(Wehrmann et al., 2002). All other studies used the Bispectral IndexTM monitor. In most 
trials, specific criteria were set to guide clinicians’ decision-making for sedation titration 
based on depth of anaesthesia monitoring measurements. Sedation in the control groups 
was typically titrated according to scores on a sedation scale (e.g. the Observer’s 
Assessment of Alertness/Sedation). The most common sedative used was propofol. Other 
medications used were midazolam, remifentanil, alfentanil, ketamine and pethidine. All 
except one study excluded children (Baysal et al., 2008). One trial involved two phases, so 
the data from each phase were included in meta-analysis separately (Drake et al., 2006). 
One trial utilised a cross-over design, in which sufficient time was allowed between 
procedures to ensure there was no carry-over effect (Jang et al., 2012). We attempted to 
contact the authors of this trial in order to retrieve pre cross-over data to include in the 
meta-analysis. A response was not received. Patients judged to be American Society of 
Anesthesiology Physical Classification Status IV were excluded from most of the studies 
(defined as a patient with severe systemic disease that is a constant threat to life). 
Summaries of the judgements of the risk of bias of included trials are presented in a 
Supplementary File (S3 Figure). 
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Table 1 Characteristics of included trials 
Author (Year) Design Number of 
Participants 
Population characteristics Interventions Comparison Outcomes 
 
Baysal et al. 
(2008) 
Parallel 126 • Children undergoing 
cardiac catheterisation 
• American Society of 
Anesthesiology 
Physical Classification 
Status Class I-II 
• Benzodiazepine and 
ketamine used for 
sedation 
Bispectral IndexTM 
monitoring by an 
anaesthetist with 
sedation titrated to 
maintain scores 
between 60 and 85 
Sedation titrated 
according to a 
sedation scale 
• Oxygen desaturation of more 
than 5 point decrease from 
baseline 
• Decrease in systolic blood 
pressure of >20% 
• Amount of sedative medications 
administered (benzodiazepine 
and ketamine) 
 
Dahaba et al. 
(2006) 
Parallel 54 • Adult patients over 40 
years of age 
undergoing a painful 
procedure in an 
interventional 
radiology department 
• Remifentanil and 
propofol was used for 
sedation 
Bispectral IndexTM 
scores were used to 
titrate sedation 
The  Sedation 
agitation scale 
was used to 
titrate sedation 
• Sedation recovery, which was 
defined as date of birth recall 
with normal respiratory rate 
(>10/min) 
• Amount of sedation 
administered 
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von Delius et al. 
(2012) 
Parallel 144 • Adult patients 
undergoing  ERCP 
• American Society of 
Anesthesiology 
Physical Classification 
Status I-III 
• Excluded patients with  
Pre-existing 
hypotension, 
bradycardia, 
hypoxaemia or 
supplemental oxygen 
• Propofol and 
midazolam was used 
for sedation 
Bispectral IndexTM 
scores were 
available 
Bispectral IndexTM 
scores not 
available 
• Hypoxaemia (SpO2 less than 
90%) 
• Severe hypoxaemia below 85% 
• Hypotension (systolic blood 
pressure less than 90mmHg) 
• Sedation recovery defined as 
time until: eye opening; verbal 
response; and leaving procedure 
room 
• Amount of propofol 
administered 
• Mortality during the procedure 
DeWitt (2008) Parallel 50 • Adult patients 
undergoing  
endoscopic ultrasound 
• Propofol was used for 
sedation 
Sedation was 
titrated to a  
Bispectral IndexTM  
score of 65-75 
Sedation was 
titrated to 
Modified 
Observer’s 
Assessment of 
Alertness/Sedatio
n score <3 
• Hypoxaemia (SpO2 less than 
90%) 
• Hypotension (systolic blood 
pressure less than 90mmHg) 
• Amount of propofol 
administered 
• Positive pressure ventilation 
required 
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Drake et al. 
(2006) 
Parallel 105 • Adult patients 
undergoing  
colonoscopy 
• American Society of 
Anesthesiology 
Physical Classification 
Status I-III 
• Propofol was used for 
sedation 
Bispectral IndexTM 
used as an adjunct in 
first phase and to 
titrate sedation to 
scores greater than 
70 in the second 
phase 
No  Bispectral 
IndexTM 
• Hypoxaemia (SpO2 less than 
90%) 
• Hypotension (systolic blood 
pressure less than 90mmHg) 
• Amount of propofol 
administered 
• Sedation recovery defined as  
blood pressure within 20% of 
baseline, oriented to person, 
place and time, having a steady 
gait, minimal or no complaint of 
pain, nausea or vomiting, and 
had taken oral fluids. 
• Assisted ventilation 
Fruchter et al. 
(2014) 
Parallel 81 • Adult patients 
undergoing  
bronchoscopy 
• Propofol was used for 
sedation 
Sedation was 
titrated to a  
Bispectral IndexTM 
score of 70-85 
Sedation titrated 
to Observer’s 
Assessment of 
Alertness/Sedatio
n scores 2-4 
• Hypoxaemia (SpO2 less than 
90%) 
• Hypotension (systolic blood 
pressure less than 90mmHg) 
• Amount of propofol 
administered 
Imagawa et al. 
(2008) 
Parallel 156 • Adult patients 
undergoing  
endoscopic 
submucosal dissection 
• Propofol was used for 
sedation 
Sedation was 
titrated to a  
Bispectral IndexTM 
score of 60-80. 
Doses administered 
if  Bispectral IndexTM 
>85 
Sedation titrated 
to Observer’s 
Assessment of 
Alertness/Sedatio
n scores 2-4 
• Hypoxaemia (SpO2 less than 
90%) 
• Hypotension (systolic blood 
pressure less than 90mmHg) 
• Amount of propofol 
administered 
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Jang et al. 
(2012) 
Cross-over 59 • Adult patients 
undergoing  
endoscopic ultrasound 
• Propofol, 
benzodiazepines and 
opioids were used for 
sedation 
• American Society of 
Anesthesiology 
Physical Classification 
Status I-III 
Sedation was 
titrated to a  
Bispectral IndexTM 
score of 65-80 
No  Bispectral 
IndexTM 
• Oxygen saturation below 80% 
>15 seconds 
• Systolic blood pressure below 
80mmHg 
• Amount of sedation 
administered 
• Number of procedures not 
completed 
Kang et al. 
(2011) 
Parallel 56 • Adult patients 
undergoing  
endoscopic 
submucosal dissection 
• Benzodiazepine/opioid 
combination  was used 
for sedation 
• American Society of 
Anesthesiology 
Physical Classification 
Status I-III 
Sedation was 
titrated to a  
Bispectral IndexTM 
score of 65-80 
Sedation was 
titrated to 
Modified 
Observer’s 
Assessment of 
Alertness/Sedatio
n score of 2 or 3 
• Hypoxaemia (SpO2 less than 
90%) 
• Hypotension (systolic blood 
pressure less than 90mmHg) 
• Amount of sedation 
administered 
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Lin et al. (2011) Parallel 220 • Patients undergoing 
percutaneous 
vertebroplasty 
• American Society of 
Anesthesiology 
Physical Classification 
Status II-III 
• Monitored 
anaesthesia care with 
propofol, midazolam 
and fentanyl 
Propofol was 
increased if auditory 
evoked potential >50 
or decreased if <25. 
Midazolam was 
administered if 
auditory evoked 
potential >50  when 
max propofol dose 
(2mcg/mL) was 
reached. 
Propofol was 
increased if  
Observer’s 
Assessment of 
Alertness/Sedatio
n >2 or decreased 
if <2 
Midazolam was 
administered if  
Observer’s 
Assessment of 
Alertness/Sedatio
n >2 when max 
propofol dose 
(2mcg/mL) was 
reached. 
• Hypoxaemia (defined as oxygen 
saturation below 90% and 
apnoeic) 
• Hypotension (systolic blood 
pressure less than 90mmHg) 
• Amount of sedation 
administered 
• Number of procedures not 
completed 
Lo et al. (2011) Parallel 500 • Adult patients 
undergoing  
bronchoscopy 
• Benzodiazepine/opioid 
combination  was used 
for sedation 
• American Society of 
Anesthesiology 
Physical Classification 
Status I-III 
 
Sedation was 
titrated to a  
Bispectral IndexTM 
score of 65-75 
No  Bispectral 
IndexTM 
• Hypoxaemia (SpO2 less than 
90%) 
• Hypotension (systolic blood 
pressure less than 90mmHg) 
• Amount of sedation 
administered 
• Sedation recovery  defined as 
orientation to time (could 
perform the finger to nose test) 
and time to ambulation 
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Miner et al. 
(2005) 
Parallel 105 • Adult patients 
undergoing a 
procedure in an 
emergency 
department 
• Propofol was used for 
sedation 
Bispectral IndexTM  BIS blinded • Hypoxaemia (SpO2 less than 
90%) 
• Decrease in systolic blood 
pressure of >20% 
• Amount of propofol 
administered 
• Number of procedures not 
completed 
• Assisted ventilation 
Park et al. 
(2014) 
Parallel 180 • Adult patients 
undergoing  
endoscopic 
submucosal dissection 
• Propofol and 
remifentanil was used 
for sedation 
• American Society of 
Anesthesiology 
Physical Classification 
Status I-III 
Sedation was 
titrated to a  
Bispectral IndexTM 
score of 68-75 
Sedation was 
titrated to 
Modified 
Observer’s 
Assessment of 
Alertness/Sedatio
n score of 1-2 
• Hypoxaemia (SpO2 less than 
90%) 
• Systolic blood pressure below 
80mmHg 
• Amount of sedation 
administered 
• Time required to achieve 
recovery from sedation (defined 
as Aldrete recovery score >7) 
• Time to eye opening and time to 
leaving recovery 
• Mortality during the procedure 
Paspatis et al. 
(2009) 
Parallel 90 • Adult patients 
undergoing  ERCP 
• American Society of 
Anesthesiology 
Physical Classification 
Status I-III 
• Propofol infusions 
were used 
 
Sedation was 
titrated to a  
Bispectral IndexTM 
score of 40-60 
Sedation was 
titrated to 
Modified 
Observer’s 
Assessment of 
Alertness/Sedatio
n score of 0 
• Hypoxaemia (SpO2 less than 
90%) 
• Apnoea for more than 15 
seconds 
• Hypotension (systolic blood 
pressure less than 90mmHg) 
• Amount of propofol 
administered 
• Time required to achieve 
recovery from sedation (defined 
as Aldrete recovery score >7) 
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American Society of Anesthesiology Physical Classification Status: I=A normal healthy patient; II=A patient with mild systemic disease; III=A patient with 
severe systemic disease; IV=A patient with severe systemic disease that is a constant threat to life.
Wehrmann et 
al. (2002) 
Parallel 90 • Adult patients 
undergoing  ERCP 
• American Society of 
Anesthesiology 
Physical Classification 
Status I-IV 
• Boluses doses of 
propofol were used 
 
Raw 
electroencephalogra
m monitoring was 
used 
Electroencephalo
gram monitoring 
was not used 
• Hypoxaemia (SpO2 less than 
90%) 
• Severe hypoxaemia below 85% 
• Hypotension (systolic blood 
pressure less than 90mmHg) 
• Amount of propofol 
administered 
• Sedation recovery defined as 
time to being conversant and 
awake 
• Assisted ventilation 
Yu et al. (2013) Parallel 122 • Adult patients 
undergoing  
colonoscopy 
• American Society of 
Anesthesiology 
Physical Classification 
Status I-III 
• Propofol and a 
benzodiazepine was 
used for sedation 
Additional sedation 
was administered 
when  Bispectral 
IndexTM score was 
less than 81 
No  Bispectral 
IndexTM 
• Hypoxaemia (SpO2 less than 
90%) 
• Hypotension (systolic blood 
pressure less than 90mmHg) 
• Amount of sedation 
administered 
• Time required to achieve 
recovery from sedation (defined 
as Aldrete recovery score >8) 
• Requirement for tracheal 
intubation and mechanical 
ventilation 
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Overall, there was a high risk of bias due to lack of allocation concealment and blinding of 
participants and outcome assessments. As the trials were of short duration in an 
environment that was conducive to a low attrition rate, there was a low risk of attrition bias. 
We did not judge there to be a high risk of bias due to selective reporting for any of the 
included trials. One other potential source of bias was identified in one of the included 
trials. The group randomised to receive depth of anaesthesia monitoring was administered a 
different sedative medication (propofol) to the control group (midazolam) (Lo et al., 2011). 
For this reason, we did not include data from this trial in our meta-analyses. We attempted 
to contact authors of two studies to clarify details about reported outcomes, but we did not 
receive a response (Drake et al., 2006, Miner et al., 2005). A summary of the findings, 
including assessment of the quality of evidence for each outcome, is presented in Table 2.
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Table 2 Summary of Findings 
Outcomes Illustrative comparative risks* (95% CI) Relative 
effect 
(95% CI) 
No of Participants 
(trials) 
Quality of the 
evidence 
(GRADE) 
Comments 
Assumed risk Corresponding risk 
 Standard 
monitoring 
Depth of 
anaesthesia 
monitoring 
    
Hypoxaemia (percentage 
of haemoglobin saturated 
with oxygen <90%) 
193 per 1000 168 per 1000 
(129 to 216) 
RR 0.87 
(0.67 to 1.12) 
766 
(8) 
moderate1  
Subgroup: Interventional 
endoscopy with propofol 
infusions 
103 per 1000 88 per 1000 
(50 to 155) 
RR 0.86 
(0.49 to 1.94) 
434 
(4) 
low2 
Hypotension (systolic 
blood pressure <90mmHg) 
45 per 1000 43 per 1000 
(24 to 76) 
RR 0.96  
(0.54 to 1.7) 
942 
(8) low
2  
Procedures not completed 
due to inadequate 
sedation 
32 per 1000 17 per 1000 
(5 to 58) 
RR 0.54  
(0.16 to 1.8) 
218 
(2) 
low2 All procedures were 
completed in both groups 
in a further trial with 220 
participants that could not 
be included in this meta-
analysis (Lin et al., 2011). 
Duration of recovery from 
sedation 
 Recovery duration 
was 0.4 standard 
deviations lower 
for depth of 
anaesthesia 
monitoring 
(0.8 lower to 0.02 
lower) 
 
 809 
(8) 
very low3 Recovery duration was 
measured inconsistently 
across trials 
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Total amount of sedation 
administered 
      
Subgroup: Interventional 
endoscopy with propofol 
infusions 
The mean propofol 
dose in the control 
groups ranged from 
339mg to 584mg 
The mean propofol 
dose (mg) in the 
intervention groups 
was 
51mg lower 
(89mg lower to 
13mg lower) 
 434 
(4) 
moderate1  
*The basis for the assumed risk is the median control group risk across studies or the average risk for pooled data. The corresponding risk (and its 95% 
confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). 
CI: Confidence interval; RR: Risk ratio. 
GRADE Working Group grades of evidence: High quality Further research is very unlikely to change our confidence in the estimate of effect; Moderate quality 
Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate; Low quality Further research 
is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate; Very low quality We are very 
uncertain about the estimate. 
1 Downgraded by 1 level because of risk of bias (unclear concealment of allocation concealment and no blinding of outcome assessment for most trials)  
2 Downgraded by 2 levels because of risk of bias (unclear concealment of allocation concealment and no blinding of outcome assessment for most trials) and 
imprecision 
3 Downgraded by 3 levels because of risk of bias (unclear concealment of allocation concealment and no blinding of outcome assessment for most trials), 
inconsistency of results and differences in outcome reporting 
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Safety 
Hypoxaemia 
A total of 8 trials that reported on the number of hypoxaemic episodes (defined as a 
percentage of haemoglobin saturated with oxygen of less than 90%) observed in 766 
participants were included in the meta-analysis. There was no difference in hypoxaemia 
between groups (RR 0.87; 95% CI=0.67 to 1.12) (Figure 2). The quality of this evidence was 
downgraded because it was unclear how the allocation sequence was concealed and 
outcome assessment was not blinded for most trials.   
Sub-group analysis of four trials (434 participants) that investigated the effect of depth of 
anaesthesia monitoring using Bispectral IndexTM for patients undergoing interventional 
endoscopy procedures (endoscopic retrograde cholangiopancreatography  or endoscopic 
submucosal dissection) with propofol infusions was also undertaken. Again, no difference in 
the rate of hypoxaemia was found (RR 0.86; 95% CI=0.49-1.51; downgraded to low quality 
due to concerns about study limitations and the imprecise effect estimate).  One of the trials 
(126 children undergoing cardiac catheterisation) that used a different definition for 
hypoxaemia identified a reduction (which was not statistically significant) in desaturation in 
the depth of anaesthesia monitoring group (RR 0.39; 95% CI=0.15 to 1.03; p=0.06) (Baysal et 
al., 2008).  
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Figure 2 Meta-analysis for hypoxaemia (SpO2 <90%) 
Hypotension 
No difference in hypotension (systolic blood pressure less than 90 mmHg) was observed 
between depth of anaesthesia and standard monitoring in individual studies or on meta-
analysis of results from the 942 participants who were enrolled in eight of the included trials 
(RR 0.96; 95% CI=0.54-1.70; downgraded to low quality due to concerns about study 
limitations and the imprecise effect estimate) (Figure 3). Sub-analysis performed on three 
trials (390 participants) that compared depth of anaesthesia monitoring using Bispectral 
IndexTM during interventional endoscopy with propofol infusions also revealed no difference 
in hypotension between groups (RR 0.78; 95% CI=0.31 to 1.99). 
 
Figure 3 Meta-analysis for hypotension (systolic blood pressure <90mmHg) 
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Sedation-related adverse events 
A total of seven trials (765 participants) specifically reported data on the number of serious 
sedation-related adverse events, such as death, disability, unplanned intensive care 
admission or assisted ventilation. One participant in the depth of anaesthesia monitoring arm 
of a trial (100 participants) conducted in the emergency department setting required 
assisted ventilation (Miner et al., 2005). Two participants in each group required assisted 
ventilation due to hypercapnia in a trial (81 participants) of Bispectral IndexTM monitoring 
during flexible bronchoscopy with propofol sedation (Fruchter et al., 2014). One participant 
in the control arm of a trial that compared BIS monitoring during propofol sedation with 
midazolam and meperidine sedation without BIS during bronchoscopy required sedation 
reversal after the procedure and ICU admission (Lo et al., 2011). No other serious sedation-
related adverse events were reported. 
Sedation efficacy 
Amount of sedation administered 
Meta-analysis of 9 trials (1131 participants) that reported on the amount of propofol that 
was used during procedures revealed there was no difference between depth of 
anaesthesia and standard monitoring. However, statistically significant heterogeneity was 
detected so only results subgroup analyses were used. Two trials investigated depth of 
anaesthesia monitoring using Bispectral IndexTM during colonoscopy with bolus doses of 
propofol (Drake et al., 2006, Yu et al., 2013). There was no difference in the amount of 
propofol administered in either trial.  A further subgroup analysis was conducted on four 
trials with 434 participants who underwent interventional endoscopy procedures with 
propofol infusions to maintain sedation and were randomised to depth of anaesthesia 
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monitoring with Bispectral IndexTM or standard monitoring. The mean difference in propofol 
used in the depth of anaesthesia monitoring with Bispectral IndexTM group was -51mg (95% 
CI=-88.7 to -13.3mg; downgraded to moderate quality due to concerns about study 
limitations). A further 3 trials, which reported the amount of propofol used, were not 
included in the meta-analysis (Dahaba et al., 2006, Fruchter et al., 2014, Miner et al., 2005). 
One of these trials, which was conducted with participants who underwent interventional 
radiology procedures, reported that the amount of sedation used was less in the depth of 
anaesthesia monitoring group (mean difference propofol dose -0.33mg/kg/hr [95% CI=-0.56 
to -0.10]; mean difference remifentanil dose -0.02mcg/kg/hr [95% CI=-0.04 to -0.01]) 
(Dahaba et al., 2006). A higher dose of midazolam was used for participants randomised to 
depth of anaesthesia monitoring with Bispectral IndexTM who underwent endoscopic 
submucosal dissection with a sedation regimen consisting of midazolam and meperidine 
(mean difference 1.4 mg; 95% CI=0.26 to 2.54mg) (Kang et al., 2011).  Depth of anaesthesia 
monitoring resulted in lower doses of midazolam and ketamine being required to sedate 
children aged 1 to 6 years undergoing cardiac catheterisation (Baysal et al., 2008). 
Procedures not completed due to inadequate sedation  
Meta-analysis of results from two trials that reported on the number of procedures that 
were not completed due to inadequate sedation revealed there was no difference between 
the depth of anaesthesia and standard monitoring groups (RR 0.54; 95% CI=0.16-1.8; 
downgraded to low quality due to concerns about study limitations and the imprecise effect 
estimate) (Jang et al., 2012, Miner et al., 2005). All procedures were completed in both 
groups in a further trial with 220 participants (Lin et al., 2011). 
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Duration of recovery from sedation 
Recovery from sedation was measured inconsistently across the included trials. 
Standardised mean difference was calculated using meta-analysis of results from 8 trials 
(809 participants). The difference in recovery time between depth of anaesthesia and 
standard monitoring groups was not clinically significant (standardised mean difference -
0.41; 95% CI -0.8 to -0.02; I2=86%). The quality of evidence was downgraded to very low 
quality due to study limitations, inconsistency and imprecision. 
Discussion 
We identified that depth of anaesthesia monitoring did not improve the safety of 
procedural sedation and analgesia by reducing hypoxaemia. Similarly, there was no 
difference in hypotension or the number of procedures that could not be completed due to 
inadequate sedation between depth of anaesthesia and standard monitoring. Furthermore, 
the reduction in duration of sedation recovery observed in the included trials was not 
clinically significant. A marked reduction in hypoxaemia (4.5% to 0.1%) was observed after 
the implementation of Bispectral IndexTM in a large non-randomised pre-post study of 1766 
patients undergoing procedures with moderate sedation administered by nurses (Yang et 
al., 2014). Unmeasured confounding variables that were not controlled in the observational 
study might have explained why the rate of hypoxaemia was reduced in the post Bispectral 
IndexTM implementation cohort because these results directly contrast with our meta-
analysis. Even with the increased statistical power gained from combining results from 
multiple trials, a statistically significant reduction in hypoxaemia was not observed in 
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patients who were randomised to depth of anaesthesia monitoring during procedural 
sedation and analgesia in our meta-analysis. Reassuringly, statistically significant 
heterogeneity was not detected (chi2=0.89; I2=0%) despite the different sedative 
medications and types of depth of anaesthesia monitoring devices used in the trials as well 
as the large difference in rates of hypoxaemia between the control groups from studies 
conducted with diverse populations. Therefore, our results suggest that there is no need to 
invest in purchasing extra equipment or training staff who are not familiar with this 
technology (i.e. nurses who don’t routinely use depth of anaesthesia monitoring during 
general anaesthesia) because there is no high quality evidence supporting the clinical 
benefits of using depth of anaesthesia monitoring during procedural sedation and analgesia. 
However, depth of anaesthesia monitoring did impact clinical decision-making regarding 
sedation titration during interventional endoscopy and radiology procedures undertaken 
with propofol infusions as well as in a single trial of procedural sedation and analgesia in 
children (Baysal et al., 2008). For this reason, it seems reasonable for clinicians who already 
have access to and are trained in its use, (i.e. anaesthetists who use depth of anaesthesia 
monitoring during general anaesthesia) to utilise depth of anaesthesia monitoring for these 
select populations of patients if it is decided that limiting the amount of sedation would be 
beneficial for the individual patient. In this regard, it should also be noted that clinical 
benefits of depth of anaesthesia monitoring in select populations of patients, such as 
children and those who undergo interventional procedures with propofol infusions for 
sedation, might be detected if larger trials are conducted because this technology did 
impact clinical decision-making regarding sedation titration. However, estimates from our 
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meta-analyses suggest that any impact is likely to be small and would require trials with very 
large sample sizes for confirmation, which may not be feasible. 
A potential explanation for the results from our meta-analyses is that depth of anaesthesia 
monitoring devices might not reliably detect changes in level of consciousness in the stages 
of the continuum of anaesthesia that are intended to be induced during procedural sedation 
and analgesia, being moderate and deep sedation. For example, BIS monitoring was found 
to be unable to discriminate between mild to moderate sedation or moderate to deep 
sedation in a study of patients undergoing procedures with sedation in the emergency 
department (Gill et al., 2003).  
An alternative explanation for our findings is that electroencephalography may not provide 
much additional information that is useful for clinicians to guide sedation titration that can’t 
already be derived from clinical observation. Changes in depth of anaesthesia during 
sedation can be assessed by determining patient’s responses to increasing levels of 
stimulation. This is not the case for general anaesthesia, where a total lack of response to 
stimuli is purposefully induced. Therefore, regardless of whether depth of anaesthesia 
monitors are reliable for discriminating between moderate and deep levels of sedation, 
results from our meta-analysis are consistent with previous research in the general 
anaesthesia context that indicated using processed electroencephalography does not seem 
to confer substantial additional clinical benefits when compared against other methods of 
depth of anaesthesia monitoring for guiding titration of anaesthesia. In a large trial of over 
6000 patients undergoing general anaesthesia who were randomised to either Bispectral 
IndexTM monitoring or end-tidal anaesthetic agent concentration monitoring, no clinical 
benefit of depth of anaesthesia monitoring was observed (Avidan et al., 2011). In contrast, 
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the B-Aware trial found that depth of anaesthesia monitoring with Bispectral IndexTM 
compared to routine care during general anaesthesia reduced the risk of awareness (Myles 
et al., 2004). Accordingly, clinical guidelines currently only recommend that depth of 
anaesthesia monitoring should be used for total intravenous anaesthesia but not for 
inhalational anaesthesia, where end-tidal anaesthetic agent concentration monitoring can 
be used to guide titration of anaesthesia (NICE, 2012). 
It should be noted that the evidence from randomised controlled trials concerning depth of 
anaesthesia monitoring during procedural sedation and analgesia was almost exclusively 
derived from an adult population who were at low risk of anaesthetic complications, as 
patients meeting American Society of Anesthesiology Physical Classification Status IV were 
excluded from most studies. Changes in level of consciousness may be more difficult to 
appreciate using clinical observation in the paediatric population. A more recently published 
observational study reported that sedation titration was aided by the use of BIS for open 
muscle biopsy in children (Tschiedel et al., 2015). Therefore, further research into depth of 
anaesthesia monitoring during procedural sedation and analgesia in children might be 
worthwhile. It is also important to note that the randomised controlled trial evidence 
identified in this review is almost exclusively limited to the Bispectral IndexTM device. This is 
consistent with the literature from the general anaesthesia context. The National Institute 
for Health and Care Excellence concluded that the evidence for the use of other available 
depth of anaesthesia monitors, including E-Entropy, Narcotrend-Compact M, is less certain 
than for Bispectral IndexTM (NICE, 2012). It is therefore uncertain whether further research 
using depth of anaesthesia monitoring devices other than the BIS for procedural sedation 
and analgesia would produce dissimilar results to those reported in the trials included in our 
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review. Another important consideration is that evidence from meta-analyses of some 
outcomes included in our review was judged to be of very low or low quality according to 
the GRADE criteria. For this reason, conducting further research of better quality (i.e. 
randomised trials adhering to CONSORT recommendations for allocation concealment and 
blinding of outcomes assessment with larger sample sizes to improve effect estimate 
precision) would increase confidence in our estimates of the potential clinical benefits of 
depth of anaesthesia monitoring during procedural sedation and analgesia.  
Due to an insufficient number of included trials, we were unable to use funnel plots to 
investigate publication bias.  However, we comprehensively searched multiple databases 
and registries, attempted to obtain and include data not reported in the included trials and 
did not impose language restrictions to minimise reporting bias (Glasziou et al., 2002). A 
recently published meta-analysis reported that using bispectral index during procedural 
sedation and analgesia for endoscopy did not improve patient or proceduralist satisfaction 
(Park et al., 2015). We did not extract data about these outcomes for our systematic review 
because we made the decision when designing our protocol that they would be susceptible 
to a very high risk of performance bias (due to the inability to blind proceduralists and 
patients). Nevertheless, it should be noted that being conservative and instead using the 
rate of incomplete procedures to provide an indication as to whether depth of anaesthesia 
monitoring improved the efficacy of sedation is a potential limitation of this review. 
Conclusion  
The evidence accumulated to date from randomised controlled trials suggests depth of 
anaesthesia monitoring should not be implemented into routine clinical practice in an effort 
to improve the safety or efficacy of procedural sedation and analgesia. Clinical benefits of 
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depth of anaesthesia monitoring in select populations of patients, such as children and 
those who undergo interventional procedures with propofol infusions for sedation, might be 
detected if larger trials are conducted because this technology did impact clinical decision-
making regarding sedation titration.  
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